The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers
Open accessAbstract
Methadone inhibits the cardiac potassium channel hERG and can cause a prolonged QT interval. Methadone is chiral but its therapeutic activity is mainly due to (R)-methadone. Whole-cell patch-clamp experiments using cells expressing hERG showed that (S)-methadone blocked the hERG current 3.5-fold more potently than (R)-methadone (IC50s (half-maximal inhibitory concentrations) at 37 degrees C: 2 and 7 microM). As CYP2B6 slow metabolizer (SM) status results in a reduced ability to metabolize (S)-methadone, electrocardiograms, CYP2B6 genotypes, and (R)- and (S)-methadone plasma concentrations were obtained for 179 patients receiving (R,S)-methadone. The mean heart-rate-corrected QT (QTc) was higher in CYP2B6 SMs (*6/*6 genotype; 439+/-25 ms; n=11) than in extensive metabolizers (non *6/*6; 421+/-25 ms; n=168; P=0.017). CYP2B6 SM status was associated with an increased risk of prolonged QTc (odds ratio=4.5, 95% confidence interval=1.2-17.7; P=0.03). This study reports the first genetic factor implicated in methadone metabolism that may increase the risk of cardiac arrhythmias and sudden death. This risk could be reduced by the administration of (R)-methadone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995) · Cell · doi:10.1016/0092-8674(95)90340-2 · Cited by 2,423
Eap, C. B., Buclin, T., & Baumann, P. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241140-00003 · Cited by 599
Self-citationLang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 574
Torsade de Pointes Associated with Very-High-Dose Methadone
Krantz, M. J., Lewkowiez, L., Hays, H., Woodroffe, M. A., Robertson, A. D., & Mehler, P. S. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00010 · Cited by 426
Laurel Gorman, A., Elliott, K. J., & Inturrisi, C. E. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13391-2 · Cited by 398
Codd, E. E., Shank, R. P., Schupsky, J. J., & Raffa, R. B. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10630-7 · Cited by 388
Predicting drug–hERG channel interactions that cause acquired long QT syndrome
Sanguinetti, M. C., & Mitcheson, J. S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.003 · Cited by 300
Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W.-H., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200512000-00004 · Cited by 269
Influence of Opioid Agonists on Cardiac Human Ether-a-go-go-related Gene K+ Currents
Katchman, A. N., McGroary, K. A., Kilborn, M. J., Kornick, C. A., Manfredi, P. L., Woosley, R. L., & Ebert, S. N. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038240 · Cited by 264
Ebert, B., Andersen, S., & Krogsgaard-Larsen, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11364-3 · Cited by 255
CRETTOL, S., DEGLON, J., BESSON, J., CROQUETTEKROKAR, M., HAMMIG, R., GOTHUEY, I., MONNAT, M., & EAP, C. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.012 · Cited by 250
Self-citationQTc interval prolongation associated with intravenous methadone
Kornick, C. A., Kilborn, M. J., Santiago-Palma, J., Schulman, G., Thaler, H. T., Keefe, D. L., Katchman, A. N., Pezzullo, J. C., Ebert, S. N., Woosley, R. L., et al. (2003) · Pain · doi:10.1016/s0304-3959(03)00205-7 · Cited by 243
KHARASCH, E., HOFFER, C., WHITTINGTON, D., & SHEFFELS, P. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.05.003 · Cited by 238
The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine
Kristensen, K. (1995) · Life Sciences · doi:10.1016/0024-3205(94)00426-s · Cited by 234
Ehret, G. B., Voide, C., Gex-Fabry, M., Chabert, J., Shah, D., Broers, B., Piguet, V., Musset, T., Gaspoz, J.-M., Perrier, A., et al. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.12.1280 · Cited by 233
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
CRETTOL, S., DEGLON, J., BESSON, J., CROQUETTEKROKKAR, M., GOTHUEY, I., HAMMIG, R., MONNAT, M., HUTTEMANN, H., BAUMANN, P., & EAP, C. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.011 · Cited by 228
Self-citationStereoselective metabolism of methadone N‐demethylation by cytochrome P4502B6 and 2C19
Gerber, J. G., Rhodes, R. J., & Gal, J. (2004) · Chirality · doi:10.1002/chir.10303 · Cited by 228
Pearson, E. C., & Woosley, R. L. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1112 · Cited by 225
Løvlie, R., Daly, A. K., Molven, A., Idle, J. R., & Steen, V. M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00779-x · Cited by 192
The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine
Kristensen, K., Christensen, C. B., & Christrup, L. L. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00937-6 · Cited by 188
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-rime PCR
Schaeffeler, E., Schwab, M. G., Eichelbaum, M. F., & Zanger, U. M. (2003) · Human Mutation · doi:10.1002/humu.10280 · Cited by 153
Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6
Walsky, R. L., Astuccio, A. V., & Obach, R. S. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006293753 · Cited by 141
Gil, M. M. P., Sala, M., Anguera, I., Chapinal, O., Cervantes, M., Gumà, J. R., & Segura, F. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00906-8 · Cited by 113
Urinary metabolites of DL-methadone in maintenance subjects
Sullivan, H. R., & Due, S. L. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00266a009 · Cited by 109
Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce, R. D., Altice, F. L., Gourevitch, M. N., & FRIEDLAND, G. H. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219769.89679.ec · Cited by 106
High dose methadone and ventricular arrhythmias: a report of three cases
Walker, P. W., Klein, D., & Kasza, L. (2003) · Pain · doi:10.1016/s0304-3959(02)00461-x · Cited by 104
Methadone-induced Torsade de pointes tachycardias
Sticherling, C., Schaer, B. A., Ammann, P., Maeder, M. T., & Osswald, S. (2005) · Swiss Medical Weekly · doi:10.4414/smw.2005.10939 · Cited by 66
Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy
Abriel, H., Gavillet, B., Biollaz, J., & Stoller, R. (2004) · Swiss Medical Weekly · doi:10.4414/smw.2004.10532 · Cited by 57
Self-citationEffect of trazodone on hERG channel current and QT-interval
Tarantino, P., Appleton, N., & Lansdell, K. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.01.009 · Cited by 53
González, T., Arias, C., Caballero, R., Moreno, I., Delpón, E., Tamargo, J. L., & Valenzuela, C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704978 · Cited by 53
QT Interval Prolongation in Patients on Methadone With Concomitant Drugs
Piguet, V., Desmeules, J. A., Ehret, G., Stoller, R., & Dayer, P. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132347.81455.57 · Cited by 52
Torsades de Pointes Due to Methadone
Bels, D. D., Staroukine, M., & Devriendt, J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00021-w2 · Cited by 31
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“In *6/*6 carriers (S)-methadone plasma levels were increased leading to potentially higher risk of severe cardiac arrhythmias and methadone associated deaths (Crettol et al., 2005; Eap et al., 2007; Bunten et al., 2011).”
BackgroundChiral Toxicology: It's the Same Thing…Only Different
Smith, S. W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp097 · Cited by 602
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Kannankeril, P., Roden, D. M., & Darbar, D. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003723 · Cited by 440
Zanger, U. M., & Klein, K. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00024 · Cited by 345
Metadata
- Authors
- Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Déglon, J.-J., Besson, J., Croquette-Krokar, M., Carrupt, P.-A., & Abriel, H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-02-28
- Volume
- 81
- Issue
- 5
- Pages
- 719-728
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2140003901
- Cited by
- 255
- References
- 32
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.